Postavení imunoterapie v léčbě nemalobuněčného karcinomu plic

KADLEC, Bohdan. Postavení imunoterapie v léčbě nemalobuněčného karcinomu plic. Onkologie. Praha: Solen s.r.o., 2018, roč. 12/2018, č. 4, s. 185-193. ISSN 1802-4475.

Základní údaje

Originální název

Postavení imunoterapie v léčbě nemalobuněčného karcinomu plic

Název anglicky

The role of immunotherapy in the treatment of non-small cell lung cancer

Autoři

KADLEC, Bohdan

Vydání

Onkologie, Praha, Solen s.r.o. 2018, 1802-4475

---

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

odkaz Scopus

Klíčová slova česky

imunoterapie; pokročilý NSCLC; PD-1; PD-L1

Klíčová slova anglicky

Advanced NSCLC; Immunotherapy; PD-1; PD-L1

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

Lung cancer is the leading cause of cancer-related mortality in the Czech Republic and worldwide. Of all lung cancer cases at least 80 % are non-small-cell lung cancer (NSCLC). For patients with advanced-stage NSCLC, modern platinum doublet chemotherapy results in a median overall survival (OS) of 10 months. Recently, personalized therapy for patients with tumors with specific molecular biological characteristics, such as tyrosine kinase inhibitors for tumors with activating EGFR mutations, has resulted in better OS outcomes in these biologically selected subgroups. Significant improvement in overall survival (OS) has been achieved in recent years with targeted treatment, but only effective in a small amount of patients. In addition to the remarkable progress made with targeted drugs, such as EGFR and ALK inhibitors in tumor-bearing control mutations, much hope also resides in immunotherapy. Lung cancer immunotherapy has not been successful in the past. In the last decade, however, a better understanding of the immune system and identification of relevant target antigens has made it possible to test new therapies with promising results. The breakthrough treatment in NSCLC immunotherapy represent monoclonal antibodies against the immune response checkpoints, especially antibodies to the PD-1 cell death programmed receptor and its ligand PD-L1. The challenge remains to identify the most effective treatment sequence involving immunotherapy, to understand the mechanisms of resistance of checkpoint inhibitors and to identify biomarkers for the optimal benefit from immunotherapy for NSCLC patients. © 2018 SOLEN s.r.o..All Rights Reserved.

Anglicky

Lung cancer is the leading cause of cancer-related mortality in the Czech Republic and worldwide. Of all lung cancer cases at least 80 % are non-small-cell lung cancer (NSCLC). For patients with advanced-stage NSCLC, modern platinum doublet chemotherapy results in a median overall survival (OS) of 10 months. Recently, personalized therapy for patients with tumors with specific molecular biological characteristics, such as tyrosine kinase inhibitors for tumors with activating EGFR mutations, has resulted in better OS outcomes in these biologically selected subgroups. Significant improvement in overall survival (OS) has been achieved in recent years with targeted treatment, but only effective in a small amount of patients. In addition to the remarkable progress made with targeted drugs, such as EGFR and ALK inhibitors in tumor-bearing control mutations, much hope also resides in immunotherapy. Lung cancer immunotherapy has not been successful in the past. In the last decade, however, a better understanding of the immune system and identification of relevant target antigens has made it possible to test new therapies with promising results. The breakthrough treatment in NSCLC immunotherapy represent monoclonal antibodies against the immune response checkpoints, especially antibodies to the PD-1 cell death programmed receptor and its ligand PD-L1. The challenge remains to identify the most effective treatment sequence involving immunotherapy, to understand the mechanisms of resistance of checkpoint inhibitors and to identify biomarkers for the optimal benefit from immunotherapy for NSCLC patients. © 2018 SOLEN s.r.o..All Rights Reserved.